Abstract The emergence of drug resistance continues to be a major hurdle towards improving patient outcomes for the treatment of Multiple Myeloma. MTI-101 is a first-in-class peptidomimetic that binds a CD44/ITGA4 containing complex and triggers necrotic cell death in multiple myeloma cell lines. In this report. we show that acquisition of resistance to MTI-101 correlates with changes... https://jeepworldes.shop/product-category/drinkware/